Cardiac Devices In Brief
This article was originally published in The Gray Sheet
Executive Summary
Cypher in diabetics: Johnson & Johnson/Cordis' Cypher sirolimus-eluting coronary stent performs equally well in both insulin dependant and non-insulin dependent diabetics, according to 1,407-patient trial led by Ron Waksman, MD, Washington Hospital Center. Cypher linked to six-month target vessel revascularization rates of 8%, 7.9% and 6% in non-insulin dependant, insulin dependant and non-diabetic patients, respectively, according to study results presented Nov. 9 at the American Heart Association Annual Scientific Sessions in New Orleans. Study findings support results from the 160-patient Spanish DIABETES study presented at September TCT meeting in Washington, D.C. (1"The Gray Sheet" Oct. 4, 2004, p. 4)...